Cargando…

The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China

Human immunodeficiency virus-type 1 (HIV-1) CRF01_AE/B recombinants are newly emerging strains that are spreading rapidly in Southern and Eastern China. This study aimed to elucidate the molecular epidemiological characteristics of HIV-1 CRF01_AE/B recombinants in Nanjing and to explore the impact o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, You, Liu, Yangyang, Fu, Gengfeng, Lu, Jing, Li, Xiaoshan, Du, Guoping, Fei, Gaoqiang, Wang, Zemin, Li, Han, Li, Wei, Wei, Pingmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335199/
https://www.ncbi.nlm.nih.gov/pubmed/35910646
http://dx.doi.org/10.3389/fmicb.2022.936502
_version_ 1784759282906955776
author Ge, You
Liu, Yangyang
Fu, Gengfeng
Lu, Jing
Li, Xiaoshan
Du, Guoping
Fei, Gaoqiang
Wang, Zemin
Li, Han
Li, Wei
Wei, Pingmin
author_facet Ge, You
Liu, Yangyang
Fu, Gengfeng
Lu, Jing
Li, Xiaoshan
Du, Guoping
Fei, Gaoqiang
Wang, Zemin
Li, Han
Li, Wei
Wei, Pingmin
author_sort Ge, You
collection PubMed
description Human immunodeficiency virus-type 1 (HIV-1) CRF01_AE/B recombinants are newly emerging strains that are spreading rapidly in Southern and Eastern China. This study aimed to elucidate the molecular epidemiological characteristics of HIV-1 CRF01_AE/B recombinants in Nanjing and to explore the impact of these novel strains on the immunological status. A total of 1,013 blood samples from newly diagnosed HIV-1-infected patients were collected in Nanjing from 2015 to 2019, among which 958 partial Pol sequences were sequenced successfully. We depicted the molecular epidemiological characteristics of CRF01_AE/B recombinants by the molecular evolutionary analysis, Bayesian system evolution analysis, and transmission network analysis. The generalized additive mixed model was applied to evaluate the CD4(+) T-cell count change of CRF01_AE/B recombinants. The Kaplan–Meier analysis was performed to assess the time from combined antiretroviral therapy (cART) initiation to immune reconstruction. We have identified 102 CRF01_AE/B recombinants (102/958, 10.65%) in Nanjing, including CRF67_01B (45/102, 44.12%), CRF68_01B (35/102, 34.31%), and CRF55_01B (22/102, 12.57%). According to the Bayesian phylogenetic inference, CRF55_01B had a rapid decline stage during 2017–2019, while CRF67_01B and CRF68_01B have experienced a fast growth phase during 2014–2015 and then remained stable. We have constructed 83 transmission networks, in which three larger clusters were composed of CRF67_01B and CRF68_01B. CRF01_AE/B recombinants manifested a faster decrease rate of CD4(+) T-cell count than CRF_07BC but similar to CRF01_AE. The probability of achieving immune reconstruction in CRF01_AE/B recombinants was lower than CRF07_BC in the subgroup of baseline CD4(+) T-cell count at cART initiation <300 cells/μl. In summary, CRF67_01B and CRF68_01B were the major strains of CRF01_AE/B recombinants in Nanjing, which have formed large transmission clusters between Nanjing and other provinces. CRF01_AE/B recombinants might be associated with rapid disease progression and poor immune reconstruction. The continuous epidemiological monitoring of CRF01_AE/B recombinants should be highly emphasized.
format Online
Article
Text
id pubmed-9335199
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93351992022-07-30 The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China Ge, You Liu, Yangyang Fu, Gengfeng Lu, Jing Li, Xiaoshan Du, Guoping Fei, Gaoqiang Wang, Zemin Li, Han Li, Wei Wei, Pingmin Front Microbiol Microbiology Human immunodeficiency virus-type 1 (HIV-1) CRF01_AE/B recombinants are newly emerging strains that are spreading rapidly in Southern and Eastern China. This study aimed to elucidate the molecular epidemiological characteristics of HIV-1 CRF01_AE/B recombinants in Nanjing and to explore the impact of these novel strains on the immunological status. A total of 1,013 blood samples from newly diagnosed HIV-1-infected patients were collected in Nanjing from 2015 to 2019, among which 958 partial Pol sequences were sequenced successfully. We depicted the molecular epidemiological characteristics of CRF01_AE/B recombinants by the molecular evolutionary analysis, Bayesian system evolution analysis, and transmission network analysis. The generalized additive mixed model was applied to evaluate the CD4(+) T-cell count change of CRF01_AE/B recombinants. The Kaplan–Meier analysis was performed to assess the time from combined antiretroviral therapy (cART) initiation to immune reconstruction. We have identified 102 CRF01_AE/B recombinants (102/958, 10.65%) in Nanjing, including CRF67_01B (45/102, 44.12%), CRF68_01B (35/102, 34.31%), and CRF55_01B (22/102, 12.57%). According to the Bayesian phylogenetic inference, CRF55_01B had a rapid decline stage during 2017–2019, while CRF67_01B and CRF68_01B have experienced a fast growth phase during 2014–2015 and then remained stable. We have constructed 83 transmission networks, in which three larger clusters were composed of CRF67_01B and CRF68_01B. CRF01_AE/B recombinants manifested a faster decrease rate of CD4(+) T-cell count than CRF_07BC but similar to CRF01_AE. The probability of achieving immune reconstruction in CRF01_AE/B recombinants was lower than CRF07_BC in the subgroup of baseline CD4(+) T-cell count at cART initiation <300 cells/μl. In summary, CRF67_01B and CRF68_01B were the major strains of CRF01_AE/B recombinants in Nanjing, which have formed large transmission clusters between Nanjing and other provinces. CRF01_AE/B recombinants might be associated with rapid disease progression and poor immune reconstruction. The continuous epidemiological monitoring of CRF01_AE/B recombinants should be highly emphasized. Frontiers Media S.A. 2022-07-15 /pmc/articles/PMC9335199/ /pubmed/35910646 http://dx.doi.org/10.3389/fmicb.2022.936502 Text en Copyright © 2022 Ge, Liu, Fu, Lu, Li, Du, Fei, Wang, Li, Li and Wei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Ge, You
Liu, Yangyang
Fu, Gengfeng
Lu, Jing
Li, Xiaoshan
Du, Guoping
Fei, Gaoqiang
Wang, Zemin
Li, Han
Li, Wei
Wei, Pingmin
The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China
title The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China
title_full The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China
title_fullStr The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China
title_full_unstemmed The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China
title_short The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China
title_sort molecular epidemiological and immunological characteristics of hiv-1 crf01_ae/b recombinants in nanjing, china
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335199/
https://www.ncbi.nlm.nih.gov/pubmed/35910646
http://dx.doi.org/10.3389/fmicb.2022.936502
work_keys_str_mv AT geyou themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT liuyangyang themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT fugengfeng themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT lujing themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT lixiaoshan themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT duguoping themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT feigaoqiang themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT wangzemin themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT lihan themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT liwei themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT weipingmin themolecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT geyou molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT liuyangyang molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT fugengfeng molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT lujing molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT lixiaoshan molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT duguoping molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT feigaoqiang molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT wangzemin molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT lihan molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT liwei molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina
AT weipingmin molecularepidemiologicalandimmunologicalcharacteristicsofhiv1crf01aebrecombinantsinnanjingchina